KD-182

KD-182 is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy developed by Nanjing KAEDI Biotech (KAEDI Medical). It specifically targets Claudin 18.2 (CLDN18.2), a tight junction protein isoform that is highly expressed in various gastrointestinal cancers but has limited expression in normal tissues. A key feature of KD-182 is the incorporation of a human PD-1 gene knockout modification, which is designed to enhance the persistence and anti-tumor activity of the CAR-T cells within the immunosuppressive tumor microenvironment. The therapy is currently in the preclinical stage for the treatment of solid tumors, particularly gastrointestinal malignancies such as gastric, pancreatic, and esophageal cancers.

Other names

KD-182-KAEDI Medical-CLDN18.2-CAR-T cell therapy (2nd generation)CLDN18.2-CAR-T cell therapy (2nd generation)